Volume 10, Issue 4 (8-2012)                   IJRM 2012, 10(4): 363-372 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Salman S, Kumbasar S, Hacimuftuoglu A, Ozturk B, Seven B, Polat B, et al . The effect of metyrosine/prednisolone combination to oophorectomy-induced osteoporosis. IJRM 2012; 10 (4) :363-372
URL: http://ijrm.ir/article-1-291-en.html
The effect of metyrosine/prednisolone combination to oophorectomy-induced osteoporosis
Suleyman Salman1 , Serkan Kumbasar1 , Ahmet Hacimuftuoglu2 , Berna Ozturk2 , Bedri Seven3 , Beyzagul Polat2 , Cemal Gundogdu4 , Elif Demirci4 , Kadir Yildirim5 , Fatih Akcay6 , Turan Uslu7 , Ferrah Tuncel Daloglu4 , Halis Suleyman * 8
1- Department of Obstetrics and Gynecology, Igdir National Hospital, Igdir, Turkey
2- Department of Pharmacology, Ataturk University, Medical Faculty, Erzurum, Turkey
3- Department of Nuclear Medicine, Ataturk University, Medical Faculty, Erzurum, Turkey
4- Department of Pathology, Ataturk University, Medical Faculty, Erzurum, Turkey
5- Department of Physical Medicine and Rehabilitation, Ataturk University, Medical Faculty, Erzurum, Turkey
6- Department of Biochemistry, Ataturk University, Medical Faculty, Erzurum, Turkey
7- Department of Physical Medicine and Rehabilitation, Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Turkey
8- Department of Pharmacology, Ataturk University, Medical Faculty, Erzurum, Turkey , halis.suleyman@gmail .com
Abstract:   (2554 Views)
  
Background: Osteoporosis is a chronic disease characterized by a decrease in bone mineral density (BMD) and corruption of the microarchitectural structure of bone tissue.
Objective: It was investigated whether methylprednisolone had a favorable effect on osteoporotic bone tissue in Oophorectomy induced osteoporotic rats whose endogenous adrenaline levels are suppressed with metyrosine.
Materials and Methods: Bone Mineral Density, number of osteoblast-osteoclast, bone osteocalcin levels and alkaline phosphatase (ALP) measurements were performed. Obtained results were compared with that of alendronate.
Results: Oophorectomy induced osteoporosis was exacerbated by methylprednisolone. Alentronate prevented ovariectomised induced osteoporosis, but it couldn’t prevent methylprednisolone +ovariectomised induced osteoporosis in rats.
Conclusion: Combined treatment with methylprednisolon and metyrosine was the best treatment for preventing osteoporosis but metyrosine alone couldn’t prevent osteoporosis in ovariectomised rats.
Keywords: Osteoporosis, Metyrosine, Methylprednisolon, Alendronate, Ovariectomy
Full-Text [PDF 898 kb]   (523 Downloads) |   |   Full-Text (HTML)  (493 Views)  
Type of Study: Original Article |
References
1. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006; 194 (Suppl.): 3-11. [DOI:10.1016/j.ajog.2005.08.047]
2. Gilbert SM, McKiernan JM. Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol 2005; 15: 23-27. [DOI:10.1097/00042307-200501000-00006]
3. Papakitsou EF, Margioris AN, Dretakis KE, Trovas G, Zoras U, Lyritis G, et al. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women. Maturitas 2004; 47: 185-193. [DOI:10.1016/S0378-5122(03)00282-2]
4. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 1998; 83: 2239-2243. [DOI:10.1210/jc.83.7.2239]
5. Vytrisalova M, Kubena A, Vlcek J, Palicka V, Hala T, Pavelka K. Knowledge of osteoporosis correlated with hormone therapy use and health status. Maturitas 2007; 56: 21-29. [DOI:10.1016/j.maturitas.2006.05.005]
6. Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997; 32: 1247-1255. [DOI:10.3109/00365529709028155]
7. Reid IR. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14: 279-298. [DOI:10.1053/beem.2000.0074]
8. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000; 29: 228-251. [DOI:10.1016/S0049-0172(00)80011-6]
9. Tekin Y, Bozdemir AE, Banutcuoglu B. Biochemical markers and their effecting factors in assessing osteoporosis. Turk Klinik Biyokimya Dergisi 2005; 3: 73-83.
10. van Staa T, Leufkens H, Abenhaim L. Use of oral cortikosteroids and risk of fractures. Bone Miner Res 2001; 15: 993-1000. [DOI:10.1359/jbmr.2000.15.6.993]
11. Takeuchi K, Nishiwaki H, Okada M, Niida H, Okabe S. Bilateral adrenalectomy worsens gastric mucosal lesions induced by indomethacin in the rat. Role of enhanced gastric motility. Gastroenterology 1989; 97: 284-293. [DOI:10.1016/0016-5085(89)90063-2]
12. Suleyman H, Halici Z, Cadirci E, Hacimuftuoglu A, Keles S, Gocer F. Indirect role of alpha2-adrenoreceptors in anti-ulcer effect mechanism of nimesulide in rats. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 189-198. [DOI:10.1007/s00210-007-0151-0]
13. Nar A, Demirtas E, Ayhan A, Gurlek A. Effects of bilateral ovariectomy and estrogen replacement therapy on serum leptin, sex hormone binding globulin and insulin like growth factor-I levels. Gynecol Endocrinol 2009; 25: 773-778. [DOI:10.3109/09513590903159532]
14. Kelly P, Robert A. Inhibition by pregnancy and lactation of steroid-induced ulcers in the rat. Gastroenterology 1969; 56: 24-29.
15. Genant HK, Engelke K, Fuerst T, Gluer CC, Grampp S, Harris ST, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996; 11: 707-730. [DOI:10.1002/jbmr.5650110602]
16. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141-1146. [DOI:10.1056/NEJM199310143291601]
17. Hoffman BB. Therapy of hipertension. In: Brunton LL, editor. Goodman and Gilman's the pharmacological basis of therapeutics. New-york: McGraw-Hill; 2009: 845-897.
18. Albayrak A, Polat B, Cadirci E, Hacimuftuoglu A, Halici Z, Gulapoglu M, et al. Gastric anti-ulcerative and anti-inflammatory activity of metyrosine in rats. Pharmacol Rep 2010; 62: 113-119. [DOI:10.1016/S1734-1140(10)70248-6]
19. Morton RS, Dongari-Bagtzoglou AI. Cyclooxygenase-2 is upregulated in inflamed gingival tissues [Comparative Study]. J Periodontol 2001; 72: 461-469. [DOI:10.1902/jop.2001.72.4.461]
20. Bezerra MM, de Lima V, Alencar VB, Vieira IB, Brito GA, Ribeiro RA, et al. Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats [Comparative Study]. J Periodontol 2000; 71: 1009-1014. [DOI:10.1902/jop.2000.71.6.1009]
21. Suleyman H, Dursun H, Bilici M, Cadirci E, Halici Z, Gulaboglu M, et al. Relation of adrenergic receptors, which have roles in gastroprotective and anti-inflammatory effect of adrenal gland hormones, with cyclooxygenase enzyme levels in rats. J Physiol Pharmacol 2009; 60: 129-134.
22. Stewart AF, Hoecker JL, Mallette LE, Segre GV, Amatruda TT Jr, Vignery A. Hypercalcemia in pheochromocytoma. Evidence for a novel mechanism. Ann Intern Med 1985; 102: 776-779. [DOI:10.7326/0003-4819-102-6-776]
23. Mosekilde L. Primary hyperparathyroidism and the skeleton [Review]. Clin Endocrinol (Oxf) 2008; 69: 1-19. [DOI:10.1111/j.1365-2265.2007.03162.x]
24. Borekci B, Kumtepe Y, Karaca M, Halici Z, Cadirci E, Albayrak F, et al. Role of alpha-2 adrenergic receptors in anti-ulcer effect mechanism of estrogen and luteinising hormone on rats. Gynecological endocrinology. Gynecol Endocrinol 2009; 25: 264-268. [DOI:10.1080/09513590802630104]
25. Mano T, Nishimura N, Iwase S. Sympathetic neural influence on bone metabolism in microgravity (Review). Acta Physiol Hung 2010; 97: 354-361. [DOI:10.1556/APhysiol.97.2010.4.8]
26. Tiras MB, Noyan V, Yildiz A, Yildirim M, Daya S. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Hum Reprod 2000; 15: 2087-2092. [DOI:10.1093/humrep/15.10.2087]
27. Fleisch H. Biphosphonates. In: Marcus R, Friedman D, Kelsey J, editors. Osteoporosis. 2nd ed. California: San Diego Academic Press; 2001: 449-467. [DOI:10.1016/B978-012470862-4/50017-9]
28. Rosen CJ. Pathophysiology of osteoporosis. Clin Lab Med 2000; 20: 455-468. [DOI:10.1016/S0272-2712(18)30047-7]
29. Buckwalter J, Glimcher M, Cooper R, Recker R. Bone Biology. J Bone Joint Surg Am 1995; 77: 1256-1275. [DOI:10.2106/00004623-199508000-00019]
30. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003; 32: 136-141. [DOI:10.1016/S8756-3282(02)00953-5]
31. Birdwood G. Osteoporotic bone. In: G B, editor. Understanding osteoporosis and its treatment. New York: The Parthenon Publishing Group Inc; 1996: 37-54.
32. Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003; 32: 83-113. [DOI:10.1016/S0889-8529(02)00077-4]
33. Garnero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996; 59 (Suppl.): 2-9. [DOI:10.1007/s002239900168]
34. McCormick RK. Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility. Altern Med Rev 2007; 12: 113-145.
35. Eastell R. Assessment of bone density and bone loss. Osteoporos Int 1996; 6 (Suppl.): 3-5. [DOI:10.1007/BF01625232]
36. Biyikli NK, Emre S, Sirin A, Bilge I. Biochemical bone markers in nephrotic children. Pediatr Nephrol 2004; 19: 869-873. [DOI:10.1007/s00467-004-1537-6]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb